KHO Hirslanden Zürich

What KHO Hirslanden Zürich does

KHO Hirslanden Zürich (legal name: Klinik für Hämatologie & Onkologie Hirslanden Zürich AG) is a Swiss Aktiengesellschaft operating a specialized hematology and oncology clinic on the 2nd floor of Hirslanden Clinic at Witellikerstrasse 40, Zurich. The clinic provides comprehensive diagnostics, treatment, and continuity-of-care for both outpatient and inpatient patients with blood diseases and malignant tumors, including lymphomas, leukemias, multiple myeloma, and solid tumors. Its core technology portfolio spans chemotherapy, hormone therapy, targeted therapy, immunotherapy (including bispecific antibodies), high-dose therapy with stem cell replacement, and CAR-T cell therapy — with CAR-T programs established since late 2019 and CARVYKTI (cilta-cel) launched in June 2025, making Switzerland one of the first five countries worldwide to offer this BCMA-directed therapy for multiple myeloma. The clinic operates a weekly multidisciplinary tumorboard drawing specialists from medical oncology, hematology, radio-oncology, pathology, surgery, radiology, nuclear medicine, and other disciplines, and is part of the DKG-certified tumor center at Hirslanden Clinic, certified according to Swiss Cancer Network guidelines.

The business model is a fee-for-service specialty medical practice, with revenue generated from consultations, diagnostics, chemotherapy, immunotherapies, and high-cost cell therapies billed under Swiss mandatory health insurance (KVG/LAMal) — the clinic treats patients of all insurance classes. No public pricing is disclosed. GTM is reference-driven: GPs and referring physicians route patients in, often via the weekly tumorboard, while the clinic also funnels demand through clinical trial participation, professional medical education, and patient-facing content (e.g., a Spotify podcast on cancer care). As of January 1, 2026, KHO merged with Onkozentrum Zürich (OZH) as a founding member of the newly established Hirslanden Cancer Institute, consolidating outpatient oncology across multiple Zurich-region locations while retaining its separate legal entity and staff. The clinic is also an SIWF-recognized training institution for hematology and oncology and a member of SAKK and EORTC, with KHO physicians holding leadership roles in national clinical cancer research working groups.

Name

KHO Hirslanden Zürich

Legal name

Klinik für Hämatologie & Onkologie Hirslanden Zürich AG

Website

https://kho.ch

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

KHO Hirslanden Zürich is a Swiss specialty hematology and oncology clinic within Hirslanden Clinic, providing diagnostics, chemotherapy, CAR-T and stem cell therapies, and immunotherapies to patients with blood cancers and solid tumors in the Zurich region. Since January 2026, it operates as a founding member of the Hirslanden Cancer Institute following its merger with Onkozentrum Zürich.

Ownership category

akta.pro rank

Product category

Oncology and Hematology Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (6223)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industry

Bone Marrow & Stem Cell Transplant (BMT/HSCT) (HLAKAFAI)

Keywords

• Hematology oncology services
• CAR-T cell therapy
• Stem cell transplantation
• Cancer diagnostics treatment
• Clinical cancer trials

Headquarters

HQ city

Zurich

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Medical Services Revenue: Revenue generated from providing hematology and oncology medical services including diagnostics, chemotherapy, immunotherapies, cell therapies, and inpatient/outpatient treatments. Services are covered under Swiss health insurance (KVG/LAMal). The clinic treats patients of all insurance classes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

KHO Hirslanden Zürich is a specialized hematology and oncology clinic providing comprehensive diagnostics, chemotherapy, hormone therapies, targeted therapies, immunotherapies, high-dose therapies with stem cell replacement, CAR-T cell therapies, and bispecific antibody therapies. The clinic treats both outpatients and inpatients with blood diseases and malignant tumors under Swiss health insurance (KVG/LAMal) and is certified according to Swiss Cancer Network guidelines.

Product overview

KHO Hirslanden Zürich is a specialized hematology and oncology clinic providing comprehensive cancer care as part of the Hirslanden Cancer Institute. The clinic operates a unified service model offering diagnosis, treatment, and care for blood diseases and malignant tumors through integrated services including chemotherapy, immunotherapy, targeted therapy, hormone therapy, CAR-T cell therapy, and stem cell transplantation. The product portfolio centers on core treatment services (Hematology & Oncology Treatment Services, CAR-T Cell Therapy, Stem Cell Transplantation, Chemotherapy, Immunotherapy, Targeted Therapy, Diagnostic Services, Clinical Trials, and Tumor Board Services), supplemented by supportive care modules (Psycho-oncology, Complementary Medicine, Pain Therapy/Palliative Care, Genetic Counseling, and VAT Consultation). The clinic is certified according to Swiss Cancer Network guidelines and DKG standards, offering both outpatient and inpatient care.

Differentiator

Problem solved

Functional benefit

Products and services

• Hematology & Oncology Treatment Services

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Onkozentrum Zürich (OZH)coreStrategic or Co-development Partner · 1 January 2026Since January 1, 2026, KHO Hirslanden Zürich and Onkozentrum Zürich (OZH) have joined together as founding members of the newly established Hirslanden Cancer Institute. The OZH is an established outpatient oncology institution with over 30 years of experience offering consultation, diagnostics, therapy, and follow-up care at multiple locations in the Zurich region. The partnership aims to improve patient care through knowledge exchange and better coordination of processes.
• Swiss Cancer NetworkcoreOthersThe clinic is part of the tumor centre at the Hirslanden Clinic certified according to the guidelines of the Swiss Cancer Network.
• Hirslanden CliniccoreOthersKHO is located within the Hirslanden Clinic Zurich and is an integral part of the DKG-certified tumor center and the newly established Hirslanden Cancer Institute.
• SAKK - Swiss Group for Clinical Cancer ResearchcoreStrategic or Co-development PartnerThe clinic is a member of SAKK and participates in national clinical trials. KHO physicians serve in leadership roles within SAKK project groups (e.g., PD Dr. med. Alexander Siebenhüner as President of SAKK PG GI group).
• EORTC - European Organization for Research and Treatment of CancerminorStrategic or Co-development PartnerAs a member of scientific communities such as EORTC, the clinic offers experimental treatments within international clinical studies.
• Brust-Zentrum ZürichminorStrategic or Co-development PartnerCollaborative tumorboard for breast cancer cases, held Tuesdays 07:45-09:30 and Thursdays 08:00-10:00, organized by Brust-Zentrum Zürich with KHO physicians in attendance.

Scale indicators3 records

Recent moves6 records

Expansion highlights10 records

Direct peers

• Hirslanden Klinik Aarau – Tumorzentrum: Sister Hirslanden tumor center providing hematology/oncology services under the same private hospital group. Operates within the same DKG-certified framework and Swiss Cancer Network standards, with overlapping physician community and shared Hirslanden Group infrastructure — making it the most operationally comparable Hirslanden-network peer.
• Onkozentrum Zürich (OZH): Outpatient oncology institution with 30+ years of experience at multiple locations in the Zurich region. Since January 1, 2026, OZH is a co-founding member of the Hirslanden Cancer Institute alongside KHO, making it the closest historical peer in terms of geography, patient base, and outpatient oncology focus.
• Universitätsspital Zürich – Klinik für Medizinische Onkologie und Hämatologie: The academic hematology/oncology department at the University Hospital Zurich, the principal public-sector competitor for complex oncology and hematology cases in the Zurich metropolitan area. Comparable in offering chemotherapy, CAR-T, stem cell transplant, and clinical trials, and a key alternative referral destination for the same patient pool.
• Hôpitaux Universitaires de Genève (HUG) – Service d'oncologie et d'hématologie: Geneva University Hospitals' oncology and hematology service, offering comparable specialty care, CAR-T, and clinical trials for the western Swiss market. Comparable as a Swiss tertiary public-sector comprehensive cancer center with overlapping therapeutic and academic scope.
• CHUV – Centre d'oncologie et d'hématologie: Lausanne University Hospital's oncology and hematology center, providing similar multidisciplinary cancer care, CAR-T, and clinical trial access in the French-speaking Swiss market. Comparable as a Swiss university-based comprehensive cancer center covering a different but analogous catchment area.
• Kantonsspital St. Gallen – Onkologie / Hämatologie: Large cantonal hospital oncology/hematology department in eastern Switzerland, offering chemotherapy, immunotherapy, stem cell transplant, and tumorboards. Comparable as a regional tertiary specialty provider serving a defined catchment area within the Swiss healthcare system.
• Inselspital Bern – Universitäres Tumorzentrum: Comprehensive cancer center at the Bern University Hospital, offering a similar full-stack of medical oncology, hematology, CAR-T, stem cell transplant, tumorboards, and clinical trials in another major Swiss metropolitan area. Comparable as a Swiss tertiary academic/private oncology competitor and a likely destination for second-opinion referrals.

Peers

• Universitätsklinikum Heidelberg – Nationales Centrum für Tumorerkrankungen (NCT):

Broad incumbents

• Charité – Universitätsmedizin Berlin, Charité Comprehensive Cancer Center: One of Europe's largest DKG-certified comprehensive cancer centers, providing the full range of hematology, oncology, CAR-T, and stem cell transplant services as part of a much broader hospital and academic portfolio. Comparable as a DKG-certified comprehensive oncology reference center that benchmarks the same certifications KHO holds.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kho-hirslanden-z%C3%BCrich

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KHO Hirslanden Zürich